Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 11:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 479 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Oral Manifestations Clear all
Completed Phase 4 Interventional Results available

Evaluate The Pharmacokinetics and Safety Of Oxycodone Oral Solution In Pediatric and Adolescent Subjects

NCT01959204
View directory record Official record
Conditions
Pain
Interventions
Oxycodone
Drug
Lead sponsor
VistaPharm, Inc.
Industry
Eligibility
1 Month to 17 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
9
States / cities
Orange, California • Miami, Florida • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2023 · Synced Oct 14, 2026, 11:14 AM EDT
Completed Phase 1 Interventional

A 6 Month, Open-Label, Pilot Futility Clinical Trial of Oral Salsalate for Progressive Supranuclear Palsy

NCT02422485
View directory record Official record
Conditions
Progressive Supranuclear Palsy
Interventions
Salsalate
Drug
Lead sponsor
Adam Boxer
Other
Eligibility
50 Years to 85 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
San Francisco, California • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 1, 2021 · Synced Oct 14, 2026, 11:14 AM EDT
Terminated Phase 2 Interventional

Study to Evaluate the Safety and Efficacy of Oral CR845 (Difelikefalin) in Patients With Primary Biliary Cholangitis (PBC) and Moderate-to-Severe Pruritus

NCT03995212
View directory record Official record
Conditions
Cholestatic Pruritus
Interventions
CR845 1.0 mg, Placebo
Drug
Lead sponsor
Cara Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
14
States / cities
Coronado, California • Rialto, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2023 · Synced Oct 14, 2026, 11:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Effect of Suzetrigine (SUZ) on the Pharmacokinetics of Oral Contraceptives in Healthy Female Participants

NCT06820307
View directory record Official record
Conditions
Pain
Interventions
Suzetrigine, DRSP/EE, NGM/EE
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated May 29, 2025 · Synced Oct 14, 2026, 11:14 AM EDT
Recruiting Not applicable Interventional

MucoLock™ for Treatment of Stomatitis

NCT07506018
View directory record Official record
Conditions
Stomatitis, Pain, Burning Mouth, Burning Mouth Syndrome, Oral Dysesthesia
Interventions
MucoLock Oral Gel
Device
Lead sponsor
Baptist Health South Florida
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 14, 2026, 11:14 AM EDT
Completed Phase 3 Interventional Results available

Comparing the Efficacy of Oral Opioids for Outpatient Acute Pain Management After ED Discharge Discharge

NCT01402375
View directory record Official record
Conditions
Analgesia After ED Discharge for Extremity Injuries
Interventions
Hydrocodone (first trial), Codeine (first trial), Oxycodone (for second trial), Codeine (for second trial), Oxycodone (third trial), Hydrocodone (third trial)
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
21 Years to 64 Years
Enrollment
720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated May 1, 2018 · Synced Oct 14, 2026, 11:14 AM EDT
Completed No phase listed Observational Results available

LeukoSEQ: Whole Genome Sequencing as a First-Line Diagnostic Tool for Leukodystrophies

NCT02699190
View directory record Official record
Conditions
Leukodystrophy, White Matter Disease, 4H Syndrome, Adrenoleukodystrophy, AMN, ALD, ALD (Adrenoleukodystrophy), X-linked Adrenoleukodystrophy, X-ALD, Adrenomyeloneuropathy, Aicardi Goutieres Syndrome, AGS, Alexander Disease, Alexanders Leukodystrophy, AxD, ADLD, Canavan Disease, CTX, Cerebrotendinous Xanthomatoses, Krabbe Disease, GALC Deficiency, Globoid Leukodystrophy, TUBB4A-Related Leukodystrophy, H-ABC - Hypomyelination, Atrophy of Basal Ganglia and Cerebellum, HBSL, HBSL - Hypomyelination, Brain Stem, Spinal Cord, Leg Spasticity, LBSL, Leukoencephalopathy With Brain Stem and Spinal Cord Involvement and High Lactate Syndrome (Disorder), Leukoencephalopathy With Brainstem and Spinal Cord Involvement and Lactate Elevation, ALSP, CSF1R Gene Mutation, HCC - Hypomyelination and Congenital Cataract, MLC1, Megalencephalic Leukoencephalopathy With Subcortical Cysts 1, MLD, Metachromatic Leukodystrophy, PMD, Pelizaeus-Merzbacher Disease, PLP1 Null Syndrome, PLP1 Gene Duplication | Blood or Tissue | Mutations, Pelizaeus-Merzbacher-Like Disease, 1, Peroxisomal Biogenesis Disorder, Zellweger Syndrome, Refsum Disease, Salla Disease, Sialic Storage Disease, Sjögren, Sjogren-Larsson Syndrome, Van Der Knapp Disease, Vanishing White Matter Disease, Charcot-Marie-Tooth, CMT, Mct8 (Slc16A2)-Specific Thyroid Hormone Cell Transporter Deficiency, Allan-Herndon-Dudley Syndrome, Cadasil, Cockayne Syndrome, Multiple Sulfatase Deficiency, Gangliosidoses, GM2 Gangliosidosis, BPAN, Labrune Syndrome, LCC, Mucopolysaccharidoses, TBCK-Related Intellectual Disability Syndrome
Interventions
Not listed
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Up to 18 Years
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 14, 2026, 11:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate How the Body Processes 14C-VX-993 After a Single Oral Dose

NCT06886269
View directory record Official record
Conditions
Pain
Interventions
14C-VX-993
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jun 18, 2025 · Synced Oct 14, 2026, 11:14 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

The Effect of Dexamethasone on Short Term Patient Response: IV vs Oral Administration

NCT07832110
View directory record Official record
Conditions
Post Operative Pain, Acute, Periodontitis
Interventions
Dexamethasone IV injection, Dexamethasone Capsule, Placebo IV administration, Placebo capsule
Drug · Other
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 14, 2026, 11:14 AM EDT
Completed Not applicable Interventional Results available

Pain and Anxiety Management With Oral Narcotic for Pediatric Suture Repair

NCT01053637
View directory record Official record
Conditions
Children, Lacerations, Procedures, Child, Pain
Interventions
hydrocodone/acetaminophen, Sugar water
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
2 Years to 17 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 25, 2021 · Synced Oct 14, 2026, 11:14 AM EDT
Completed Phase 4 Interventional Results available

Acute Low Back Pain. Topical Diclofenac and Oral Ibuprofen.

NCT04611529
View directory record Official record
Conditions
Low Back Pain
Interventions
Ibuprofen 400 mg, Topical diclofenac
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years to 69 Years
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 14, 2026, 11:14 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Function and Form Outcomes in Patients With Facial Paralysis

NCT03974763
View directory record Official record
Conditions
Facial Paralysis, Bell Palsy
Interventions
Not listed
Lead sponsor
Tufts University
Other
Eligibility
18 Years to 75 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 5, 2019 · Synced Oct 14, 2026, 11:14 AM EDT
Completed Phase 2 Interventional Results available

Effectiveness of Oral Prednisone in Improving Physical Functioning and Decreasing Pain in People With Sciatica

NCT00668434
View directory record Official record
Conditions
Sciatica
Interventions
Prednisone, Placebo
Drug
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years to 70 Years
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
3
States / cities
Redwood City, California • Roseville, California • San Jose, California
Source: ClinicalTrials.gov public record
Updated Apr 28, 2015 · Synced Oct 14, 2026, 11:14 AM EDT
Completed Not applicable Interventional

Randomized Study of L-Baclofen in Patients With Refractory Trigeminal Neuralgia

NCT00004431
View directory record Official record
Conditions
Trigeminal Neuralgia
Interventions
L-baclofen
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 1999
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 25, 2015 · Synced Oct 14, 2026, 11:14 AM EDT
Completed Phase 2 Interventional Results available

S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis

NCT03499808
View directory record Official record
Conditions
Amorphous, Eosinophilic, and Acellular Deposit, Constipation, Diarrhea, Early Satiety, Gastrointestinal Hemorrhage, Hepatomegaly, Lymphadenopathy, Macroglossia, Nausea, Primary Systemic Amyloidosis, Purpura, Recurrent Primary Amyloidosis, Refractory Primary Amyloidosis
Interventions
Isatuximab, Laboratory Biomarker Analysis
Biological · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
345
States / cities
Anchorage, Alaska • Hot Springs, Arkansas • Burbank, California + 234 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Oct 14, 2026, 11:14 AM EDT
Completed Phase 3 Interventional Results available

Fentanyl Sublingual Spray in Treating Opioid-tolerant Cancer Patients With or Without Oral Mucositis

NCT00956254
View directory record Official record
Conditions
Mucositis, Pain, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
Fentanyl sublingual spray
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 5, 2013 · Synced Oct 14, 2026, 11:14 AM EDT
Completed Phase 2 Interventional Results available

Trial Comparing the Effects of Xyrem (Sodium Oxybate) With Placebo for the Treatment of Fibromyalgia

NCT00087555
View directory record Official record
Conditions
Fibromyalgia
Interventions
Xyrem (sodium oxybate) oral solution, Placebo
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
20
States / cities
Scottsdale, Arizona • Beverly Hills, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2012 · Synced Oct 14, 2026, 11:14 AM EDT
Withdrawn Phase 4 Interventional

Pilot Study: Effect of Dexamethasone vs Vicodin in Reducing Post-operative Pain

NCT04008043
View directory record Official record
Conditions
Oral Surgery
Interventions
Vicodin, Dexamethasone
Drug
Lead sponsor
Boston University
Other
Eligibility
21 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 13, 2019 · Synced Oct 14, 2026, 11:14 AM EDT
Completed Phase 2 Interventional Results available

Oral Acetaminophen for Post-Op Pain Management in Bariatric Surgery Patients

NCT06658574
View directory record Official record
Conditions
Post Operative Analgesia, Bariatric Surgery, Bariatric Surgery (Gastric Bypass), Bariatric Surgery Patients, Perioperative Analgesia
Interventions
Acetaminophen
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 14, 2026, 11:14 AM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy Study to Evaluate Proellex in the Treatment of Premenopausal Women With Symptomatic Endometriosis

NCT00556075
View directory record Official record
Conditions
Endometriosis
Interventions
Proellex 25 mg, Placebo, Proellex 50 mg
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 48 Years · Female only
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
17
States / cities
Tucson, Arizona • Little Rock, Arkansas • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2014 · Synced Oct 14, 2026, 11:14 AM EDT
Completed Phase 1Phase 2 Interventional

Effects of CBD/CBD-A Oral Extract on Resting-state EEG and Neuropathic Pain Symptoms After SCI

NCT05630235
View directory record Official record
Conditions
SCI - Spinal Cord Injury, Neuropathic Pain
Interventions
CBD/CBD-A, Placebo
Drug · Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 64 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 14, 2026, 11:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Oral Irritation Study of Two Experimental Mouthrinses

NCT01156376
View directory record Official record
Conditions
Oral Manifestations
Interventions
Potassium Oxalate without Fluoride, Potassium Oxalate with Fluoride, Active Comparator PO-116-A
Device
Lead sponsor
Johnson & Johnson Consumer and Personal Products Worldwide
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Fort Wayne, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 24, 2015 · Synced Oct 14, 2026, 11:14 AM EDT
Completed Phase 3 Interventional Results available

Aripiprazole Open-Label, Safety and Tolerability Study

NCT00102518
View directory record Official record
Conditions
Schizophrenia, Bipolar Disorder
Interventions
Aripiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
10 Years to 17 Years
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
50
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Costa Mesa, California + 47 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2012 · Synced Oct 14, 2026, 11:14 AM EDT
Terminated Phase 2 Interventional Results available

A Study Of The Safety And Efficacy Of PF-04191834 In Patients With Osteoarthritis Of The Knee

NCT01147458
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
PF-04191834, PF-04191834 placebo, Naproxen placebo, Naproxen
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
25
States / cities
Peoria, Arizona • Phoenix, Arizona • Anaheim, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2013 · Synced Oct 14, 2026, 11:14 AM EDT